Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYTO -- Ignore unavailable to you. Want to Upgrade?

To: chrisco who wrote (7295)	6/15/1998 1:03:00 PM
From: Webhead	Read Replies (1) \| Respond to of 8116

Two press releases just out extolling the virtues of Prostascint and even an honorable mention of Quadramet. Looks good long term... if there IS a long term... First, here is a report from the current scientific meeting of the Aumerican Urology Association and Society of Nuclear Medicine. It really sound like cytogen is finally getting off its bloated, spotted behind and starting to MARKET. Ed ---- Multiple Studies Reported at American Urology Association and Society of Nuclear Medicine Conferences Confirm the Clinical Utility of ProstaScint(R) PR Newswire - June 15, 1998 12:19 CYTO %MTC V%PRN P%PRN Jump to first matched term PRINCETON, N.J., June 15 /PRNewswire/ -- CYTOGEN Corporation's (Nasdaq: CYTO) ProstaScint(R) was the subject of multiple presentations made at the recent American Urological Association (AUA) annual meeting in San Diego and the Society of Nuclear Medicine (SNM) annual meeting in Toronto. The various studies confirm not only the role of ProstaScint in influencing patient management decisions but also emphasized its cost effectiveness. Clinicians from the University of Maryland and Loyola University presented alternative methods for acquiring and interpreting ProstaScint images. Both involved a special imaging technique which uses two isotopes simultaneously. This experimental procedure, not approved by FDA, was reported to reduce the time and costs of ProstaScint imaging. Another presentation, also from the University of Maryland, discussed correlating ProstaScint images acquired using this dual isotope technique with anatomic landmarks obtained via CT scan and/or MRI so as to aid physicians in interpreting the antibody images. Two additional studies from researchers at the Johns Hopkins' Medical Institutions presented the role of ProstaScint in identifying lymph node spread of prostate cancer in high-risk patients, in both the pre-surgical and recurrent disease settings. The value of ProstaScint in identifying metastatic foci of cancer outside the prostate was demonstrated. These studies will be reported in future publications. A meeting of ProstaScint users which was moderated by Dr. Michael Blend of the University of Chicago was held on Sunday, June 7 prior to the opening of the SNM annual meeting. The meeting was attended by 200 leading clinicians from both the United States and abroad who discussed their individual experiences with ProstaScint. There also was a featured presentation on Quadramet(R), CYTOGEN's therapeutic agent for metastatic bone pain. "The data presented at these prestigious conferences confirm the earlier clinical experience and demonstrate that ProstaScint is an invaluable diagnostic for prostate cancer detection in appropriate patients," said John E. Bagalay, President and Chief Executive Officer of CYTOGEN. "We are delighted with the high level of interest in ProstaScint shown by attendees at both these meetings." Launched in February 1997 by CYTOGEN and C.R. Bard's Urologic Division, ProstaScint is a diagnostic-imaging agent for newly diagnosed patients at high risk for the spread of prostate cancer and for post-prostatectomy patients with a high suspicion that the disease has recurred or spread. ProstaScint works by binding to a protein called Prostate Specific Membrane Antigen (PSMA) expressed by cancerous prostate cells. Since ProstaScint is combined with a radioactive agent, a special camera detects cells with PSMA, including metastatic cancer cells outside the prostate. Knowing the extent and the location of the cancer is a critical factor in selecting the best course of treatment for the patient. Prostate cancer is the second leading cause of death from cancer in males in the United States. The American Cancer Society estimates there will be 184,500 new cases of prostate cancer in the United States in 1998. The disease is common in males over sixty and accounts for over 40,000 deaths annually. CYTOGEN is a biopharmaceutical company engaged in the development, manufacture and commercialization of products for the targeted delivery of diagnostics and therapeutic substances directly to disease sites. CYTOGEN has demonstrated its ability to develop new technology from early discovery through clinical development, regulatory approval and commercial scale biologic manufacturing. Information in this press release, which is not historical, is forward looking and involves risks and uncertainties. Actual results may differ materially, for reasons discussed in CYTOGEN's filings with the Securities and Exchange Commission, including commercial acceptance of ProstaScint. SOURCE CYTOGEN Corporation /CONTACT: Corporate Communications of CYTOGEN Corporation, 609-987-8221, or Angela Bitting of Russell-Welsh, 650-312-0700, ext. 15/

To: chrisco who wrote (7295)	6/15/1998 1:07:00 PM
From: Webhead	Respond to of 8116

Here is the second PR from a different meeting focused on Prostate Cancer patients and their families. If Cytogen is finally getting the word out to both clinicians and patients this is certainly good news. Perhaps it will increase the value of a buyout :) Ed ----- CYTOGEN's ProstaScint(R) Featured at National Conference on Prostate Cancer; Patients Learn About New Tests and Treatments PR Newswire - June 15, 1998 12:20 CYTO %MTC V%PRN P%PRN Jump to first matched term NEW YORK, June 15 /PRNewswire/ -- CYTOGEN Corporation's (Nasdaq: CYTO) ProstaScint(R) Scan (capromab pendetide) was one of the products highlighted on Saturday, June 13, and Sunday, June 14, at the National Conference of The Education Center for Prostate Cancer Patients, Inc. (ECPCP) in New York. ProstaScint, a unique diagnostic imaging agent for prostate cancer, detects the location and extent of prostate cancer, providing patients and physicians with additional information they need to make the treatment decisions. Launched in February 1997 by CYTOGEN and C.R. Bard's Urologic Division, ProstaScint is a diagnostic-imaging agent for newly diagnosed patients at high risk for the spread of prostate cancer and for post-prostatectomy patients with a high suspicion that the disease has recurred or spread. ProstaScint works by binding to a protein called Prostate Specific Membrane Antigen (PSMA) expressed by cancerous prostate cells. Since ProstaScint is combined with a radioactive agent, a special camera detects cells with PSMA, including metastatic cancer cells outside the prostate. Knowing the extent and the location of the cancer is a critical factor in selecting the best course of treatment for the patient. "Prostate cancer patients need to hear about the latest treatments and diagnostic options available to them," said Dr. Daniel Petrylak from the Columbia Presbyterian Medical Center, who spoke about ProstaScint at the conference. "We are delighted that the ECPCP has provided a forum through which patients can get the information they need to help them make the most effective decisions." Prostate cancer is the second leading cause of death from cancer in males in the United States. The American Cancer Society estimates there will be 184,500 new cases of prostate cancer in the United States in 1998. It is common in males over sixty and accounts for over 40,000 deaths annually. The conference, entitled "New Hope for the Future: Recent Advances in Diagnosing and Treating Prostate Cancer," provides prostate cancer patients and their families with valuable information about new developments in prostate cancer. More than 25 leading clinicians and experts in the field participate in the conference. CYTOGEN has an active campaign to support and educate prostate cancer patients and their family members. Since the product's introduction, information about ProstaScint has been presented to over 3,500 prostate cancer patients at various support groups and symposia nationwide. CYTOGEN is pleased to support the educational efforts of such programs, and is committed to supporting prostate cancer patient awareness. The ECPCP is a nonprofit organization dedicated to saving or lengthening the lives of prostate cancer patients, to improving the quality of their lives and to enabling them to make effective diagnostic and treatment decisions through education, advice, counseling and research. By offering its members all the information available on new techniques and treatments, ECPCP hopes to empower its members to take control of their disease, rather then let the disease control them. CYTOGEN is a biopharmaceutical company engaged in the development, manufacture and commercialization of products for the targeted delivery of diagnostics and therapeutic substances directly to disease sites. CYTOGEN has demonstrated its ability to develop new technology from early discovery through clinical development, regulatory approval and commercial scale biologic manufacturing. Information in this press release, which is not historical, is forward looking and involves risks and uncertainties. Actual results may differ materially, for reasons discussed in CYTOGEN's filings with the Securities and Exchange Commission, including commercial acceptance of ProstaScint. SOURCE CYTOGEN Corporation /CONTACT: Corporate Communications of CYTOGEN, 609-987-8221, or Angela Bitting of Russell-Welsh, 650-312-0700, ext. 15/